Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 1997

View Archived Issues

Ferring permitted to resume marketing of Repronex

PharmaPrint submits IND for herbal BPH treatment

Astra: 1997 half-year highlights

Terrapin and Taiho sign development agreement for anticancer agent

New biotech company formed to combat cardiovascular diseases

FDA proposes to require pediatric data on drugs

U.S. patent issued for Candida albicans treatment method

Spanish scientists discover anxiolytic CCKA antagonist

Phase I trial of DiffGAM completed successfully

Sequana, Boehringer Mannheim closer to elucidating genetic basis of osteoporosis

Vasopressin agonist from Otsuka

Phenobarbital ineffective in stopping brain bleeding in neonates

Twinrix now available for pediatric use

Novo Nordisk: 1997 half-year highlights

GalaGen starts Diffistat-G phase II trial

VEGF RTK inhibitors in the pipeline at Zeneca

Clinical trial results announced for novel incontinence therapeutic

New treatment for osteoarthritis approved for marketing in U.S.

Patents for collagen markers issued to Ostex

Drug discovery agreement forged by Procept, Abbott

Onyx, W-L collaborate on antiinflammatory and immunomodulating agents

SmithKline Beecham donates Havrix vaccine to flood areas

Glaxo Wellcome discloses a new series of thrombin inhibitors

Sporidin-G trial put on hold

IRIS licenses patents to TOA

Delmopinol inhibits gingivitis in extreme rates of plaque formation

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026